about
Rheumatoid arthritis treatment: the earlier the better to prevent joint damagePower Doppler ultrasonographic assessment of the joint-draining lymph node complex in rheumatoid arthritis: a prospective, proof-of-concept study on treatment with tumor necrosis factor inhibitors.B cells in rheumatoid arthritis: from pathogenic players to disease biomarkers.Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs.Autoantibodies to heterogeneous nuclear ribonucleoproteins.CCL21 expression pattern of human secondary lymphoid organ stroma is conserved in inflammatory lesions with lymphoid neogenesis.Assessment of synovitis to predict bone erosions in rheumatoid arthritis.Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis.Synovial tissue heterogeneity and peripheral blood biomarkers.Early treatment in early undifferentiated arthritis.Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases.Modulating the co-stimulatory signal for T cell activation in rheumatoid arthritis: could it be the first step of the treatment?Long-term safety of abatacept in patients with rheumatoid arthritis.Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter--Determining Validation Requirements.B cell autoimmunity and bone damage in rheumatoid arthritis.Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designsThe draining lymph node in rheumatoid arthritis: current concepts and research perspectives.Baseline serum concentrations of TRAIL in early rheumatoid arthritis: relationship with response to disease-modifying antirheumatic drugs.Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis.Subclinical remodelling of draining lymph node structure in early and established rheumatoid arthritis assessed by power Doppler ultrasonography.Rheumatoid arthritis in beta-thalassemic trait: clinical, serologic and immunogenetic profile.Long term treatment of rheumatoid arthritis with rituximab.A multi centre retrospective analysis evaluating performance of synovial biopsy techniques: arthroscopic vs. ultrasound guided vs. blind needle biopsy.Use of ultrasound-guided small joint biopsy to evaluate the histopathologic response to rheumatoid arthritis therapy: recommendations for application to clinical trials.B cells in rheumatoid arthritis.B cells in rheumatoid arthritis.Clinical, Imaging, and Pathological Suppression of Synovitis in Rheumatoid Arthritis: Is the Disease Curable?Histopathology of the synovial tissue: perspectives for biomarker development in chronic inflammatory arthritidesThe Clinical Value of Autoantibodies in Rheumatoid ArthritisHigh expression levels of the B cell chemoattractant CXCL13 in rheumatoid synovium are a marker of severe diseaseThe novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synoviumUltrasonographic and MRI characterisation of the palindromic phase of rheumatoid arthritisInvolvement of subchondral bone marrow in rheumatoid arthritis: Lymphoid neogenesis and in situ relationship to subchondral bone marrow osteoclast recruitmentClinical Applications of Synovial BiopsyIncreasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis
P50
Q26777903-B1ACBC8C-32BB-4A35-B411-2CEC4ED196E4Q30825520-E2763008-40A8-49C1-9565-D2D33406A526Q33616360-61DE0987-AAAB-4ABF-97F2-669242A39372Q36085027-6A9B1B22-5E5F-4E3A-8EC2-522E0961888EQ36086132-6C51D598-04D8-453A-BEDA-62E553134D00Q36095617-2DC8514C-6DC2-4747-8904-44A7783E18D1Q36111299-DA57ADC9-A166-4726-95CA-DE0DF90CD1C0Q37315396-B3BA5DB2-8559-40AB-BFB6-91161BB3F9DFQ37918858-07A2E45F-B43B-4154-AA4E-9759D2691E7DQ37950779-64768DF4-2DA0-466B-80F7-CF4F572D25A5Q38018705-DD0C5011-E441-4E45-A1BF-AF7FC9CCDED0Q38115383-D27A2D87-A850-4909-B0A6-7568475435EEQ38116996-9B4D37BE-3770-4D28-82E2-57BA5D1AC754Q38512329-647D6664-FCA8-4944-A9DB-0FEEC84BC0D7Q39040962-974E6C14-F9D3-4E00-B86D-03E68614E8EAQ41450339-2B455099-11F7-4E7C-81DD-6CDAD357692AQ42181555-FAAAEB97-7700-44A5-B77F-8CA472413FA1Q42471542-7F369B6D-5D7E-41B7-84D4-04F8635A033CQ43096548-5AA40E77-D3EF-4C89-9C5E-AA1E7FB06D72Q43979992-6DDFA11D-AA1A-4C47-9CD6-91D061B80095Q47862920-70EFF61A-1B74-4840-BAAF-BF1860D6A8C9Q47945782-2773AA62-4483-40EC-B8CA-930010F67AE7Q50159928-5F257B36-B376-4D84-8DA8-E6AE8B7A14F7Q53459559-8B3C5E5E-6EA5-4DEE-9CCC-2D21D04BE982Q53514683-73A04F55-067D-4313-85C1-59A05AB8E946Q53539114-AFCDA35E-A7B8-471A-8DC8-55530E299FE5Q55191136-D17AD86A-DCB9-491D-A071-B5033EC196D9Q57041512-1D313285-CADC-4F76-B994-D39697CC3C48Q60047547-9A407920-401A-4D84-96DB-52714E97AF9BQ60622629-14166CE2-3101-4A3D-993A-02DD4A7FE0F2Q60622640-DEB91D84-36CE-4D99-96A9-7290822DA41FQ60622647-4E4F38D0-6438-4FD2-BDF4-ED22CFFA4460Q60622664-0787BD1E-1F75-4E2F-8362-1095815162D5Q64263638-FD771345-FD35-4FD4-B1E9-47F4D326E377Q92091111-8C6AB9B9-45C3-4B7E-BFFB-1E6F4A5A66FF
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Serena Bugatti
@ast
Serena Bugatti
@en
Serena Bugatti
@es
Serena Bugatti
@sl
type
label
Serena Bugatti
@ast
Serena Bugatti
@en
Serena Bugatti
@es
Serena Bugatti
@sl
prefLabel
Serena Bugatti
@ast
Serena Bugatti
@en
Serena Bugatti
@es
Serena Bugatti
@sl
P106
P1153
6507378453
P21
P31
P496
0000-0002-5396-7077